• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Npj Viruses . Impact of naturally occurring hemagglutinin substitutions on antigenicity and fitness of influenza A(H5N1) virus

tetano

Editor, Senior Moderator
Npj Viruses


. 2025 Oct 2;3(1):72.
doi: 10.1038/s44298-025-00154-5. Impact of naturally occurring hemagglutinin substitutions on antigenicity and fitness of influenza A(H5N1) virus

Li Wang[SUP] #[/SUP][SUP] 1 [/SUP], Masato Hatta[SUP] #[/SUP][SUP] 1 [/SUP], Chenchen Feng[SUP] #[/SUP][SUP] 1 [/SUP], Paul Carney[SUP] 1 [/SUP], Melvyn R Almanzar-Jordan[SUP] 2 [/SUP], Jieru Wang[SUP] 1 [/SUP], Jaber Hossain[SUP] 1 [/SUP], Ginger Atteberry[SUP] 1 [/SUP], Nacyra Assad-Garcia[SUP] 3 [/SUP], Sydney Sheffield[SUP] 1 [/SUP], Juliana DaSilva[SUP] 1 [/SUP], Juan A De La Cruz[SUP] 1 [/SUP], Yasuko Hatta[SUP] 1 [/SUP], Monique C Johnson[SUP] 1 [/SUP], Julia Frederick[SUP] 1 [/SUP], Rebecca Hart[SUP] 3 [/SUP], Kristine A Lacek[SUP] 1 [/SUP], Malania Wilson[SUP] 1 [/SUP], Lisa M Keong[SUP] 1 [/SUP], Xudong Lin[SUP] 1 [/SUP], Ying Huang[SUP] 1 [/SUP], Michael Currier[SUP] 1 [/SUP], Gene Tan[SUP] 4 5 [/SUP], Sanjay Vashee[SUP] 3 [/SUP], Vivien G Dugan[SUP] 1 [/SUP], Benjamin Rambo-Martin[SUP] 1 [/SUP], Han Di[SUP] 1 [/SUP], Marie K Kirby[SUP] 1 [/SUP], C Todd Davis[SUP] 1 [/SUP], James Stevens[SUP] 1 [/SUP], Bin Zhou[SUP] 6 [/SUP]



Affiliations
Abstract

In 2024, a human infection with clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) virus was identified in the United States in an individual with no known exposure. Genetic analysis revealed two hemagglutinin (HA) substitutions, P136S and A156T, which may alter viral antigenicity. Virus isolation was unsuccessful, preventing timely serologic analysis. To overcome this limitation, we generated recombinant viruses by reverse genetics and characterized the effects of the substitutions on antigenicity, receptor binding, and replicative fitness. The A156T substitution introduced a potential N-linked glycosylation site, resulting in altered antigenicity and reduced replication in primary human nasal epithelial cells and ferrets. Importantly, the A(H5N1) candidate vaccine virus (CVV) IDCDC-RG80A, which possesses HA-T156, remained antigenically effective against viruses with and without these substitutions. These findings highlight the importance of sequencing, reverse-genetics approaches, and antigenically similar CVVs such as IDCDC-RG80A, for pandemic preparedness against evolving clade 2.3.4.4b A(H5N1) viruses.


 
Back
Top Bottom